OXNARD, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced Gene Salkind, M.D. joined the company’s Advisory Board and also became the first investor of larger financing that will lead CURE to an application with the national securities exchange within the first quarter. Dr. Salkind is a highly skilled neurosurgeon and a leader in the field of neurosurgery with multiple board certifications, and a career that spans four decades. Dr. Salkind invested $1 million in CURE and will provide strategic counsel to the company’s clinical trials, partnerships and the CUREfilm technology for the central nervous system (CNS) and other therapeutic areas.
“The fact that we have the time and financing from an expert like Dr. Salkind validates what we are doing in the marketplace,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical. “His insights from a neuroscience perspective will be instrumental to CURE, as we further establish the company as a leader in non-invasive drug delivery.”
Dr. Salkind completed his neurosurgery residency training at the hospital of the University of Pennsylvania, his Neuropathology fellowship training at Children’s Hospital of Philadelphia, and his Neuroradiology fellowship training at Pennsylvania Hospital. He is a former professor at the Hospital of the University of Pennsylvania, Temple School of Medicine at Temple University, Medical College of PA and Hahnemann University Hospital in Philadelphia. Currently, Dr. Salkind is Chief of Neurosurgery at Holy Redeemer Hospital in Pennsylvania and serves as Emeritus on the board of directors for the Temple University Medical Alumni Association.
As a prolific pharmaceutical investor, some of Dr. Salkind’s previous successful investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, one of the nation's largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics.
“There is tremendous opportunity with CURE’s technology, scientific innovations and product portfolio,” said Dr. Gene Salkind. “The potential in treating patients that suffer from CNS conditions is limitless.”
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated drug delivery and development committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.